Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):378-80. doi: 10.1097/01.qai.0000180079.60945.a3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Argentina
  • Clinical Trials as Topic
  • Europe
  • Flaviviridae Infections / complications*
  • Flaviviridae Infections / diagnosis
  • GB virus C* / immunology
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1*
  • Hepatitis, Viral, Human / complications*
  • Hepatitis, Viral, Human / diagnosis
  • Humans
  • Ritonavir / therapeutic use*
  • Serologic Tests
  • Treatment Outcome
  • United States

Substances

  • Anti-Retroviral Agents
  • HIV Protease Inhibitors
  • Ritonavir